Wall Street brokerages forecast that Amedisys Inc (NASDAQ:AMED) will post earnings of $0.53 per share for the current quarter, Zacks reports. Five analysts have made estimates for Amedisys’ earnings. The lowest EPS estimate is $0.52 and the highest is $0.54. Amedisys reported earnings of $0.36 per share in the same quarter last year, which indicates a positive year over year growth rate of 47.2%. The firm is scheduled to announce its next quarterly earnings results on Thursday, November 2nd.

According to Zacks, analysts expect that Amedisys will report full-year earnings of $2.22 per share for the current financial year, with EPS estimates ranging from $2.20 to $2.24. For the next year, analysts forecast that the firm will report earnings of $2.45 per share, with EPS estimates ranging from $2.36 to $2.58. Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research firms that follow Amedisys.

Amedisys (NASDAQ:AMED) last announced its earnings results on Wednesday, July 26th. The health services provider reported $0.62 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.50 by $0.12. The business had revenue of $378.80 million for the quarter, compared to analysts’ expectations of $380.80 million. Amedisys had a return on equity of 13.71% and a net margin of 2.70%. The business’s revenue for the quarter was up 5.0% on a year-over-year basis. During the same period last year, the firm posted $0.42 earnings per share.

A number of research analysts have recently weighed in on the company. BidaskClub raised Amedisys from a “sell” rating to a “hold” rating in a report on Friday. Mizuho lowered Amedisys from a “buy” rating to a “neutral” rating and set a $50.00 price objective on the stock. in a report on Wednesday, July 26th. Royal Bank Of Canada reissued a “hold” rating and issued a $56.00 price objective on shares of Amedisys in a report on Monday, June 5th. Stephens upped their target price on Amedisys from $50.00 to $54.00 and gave the stock an “equal weight” rating in a research note on Thursday, May 4th. Finally, Benchmark Co. restated a “hold” rating and issued a $57.00 target price (up previously from $50.00) on shares of Amedisys in a research note on Wednesday, May 3rd. Six analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The company has an average rating of “Hold” and an average price target of $56.50.

ILLEGAL ACTIVITY WARNING: “Analysts Anticipate Amedisys Inc (AMED) Will Post Earnings of $0.53 Per Share” was reported by Daily Political and is the sole property of of Daily Political. If you are viewing this piece of content on another website, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark law. The correct version of this piece of content can be accessed at https://www.dailypolitical.com/2017/08/12/analysts-anticipate-amedisys-inc-amed-will-post-earnings-of-0-53-per-share.html.

In other news, insider David B. Pearce sold 1,000 shares of the company’s stock in a transaction dated Tuesday, August 8th. The stock was sold at an average price of $50.00, for a total value of $50,000.00. Following the sale, the insider now owns 10,488 shares in the company, valued at $524,400. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Bruce D. Perkins bought 500 shares of the stock in a transaction dated Thursday, May 25th. The stock was bought at an average price of $59.69 per share, for a total transaction of $29,845.00. Following the purchase, the director now directly owns 13,331 shares of the company’s stock, valued at $795,727.39. The disclosure for this purchase can be found here. 2.80% of the stock is owned by corporate insiders.

Several hedge funds have recently modified their holdings of AMED. Riverhead Capital Management LLC increased its position in shares of Amedisys by 75.5% in the second quarter. Riverhead Capital Management LLC now owns 1,931 shares of the health services provider’s stock worth $121,000 after buying an additional 831 shares in the last quarter. Federated Investors Inc. PA increased its position in shares of Amedisys by 2.3% in the second quarter. Federated Investors Inc. PA now owns 1,929 shares of the health services provider’s stock worth $122,000 after buying an additional 44 shares in the last quarter. Ameritas Investment Partners Inc. acquired a new position in shares of Amedisys during the first quarter worth about $123,000. State of Alaska Department of Revenue increased its position in shares of Amedisys by 2.3% in the first quarter. State of Alaska Department of Revenue now owns 3,080 shares of the health services provider’s stock worth $157,000 after buying an additional 70 shares in the last quarter. Finally, CIBC Asset Management Inc acquired a new position in shares of Amedisys during the second quarter worth about $230,000. Hedge funds and other institutional investors own 99.80% of the company’s stock.

Amedisys (AMED) opened at 48.88 on Friday. Amedisys has a 12 month low of $34.58 and a 12 month high of $65.91. The stock has a market capitalization of $1.66 billion, a PE ratio of 41.78 and a beta of 0.89. The firm has a 50-day moving average price of $56.08 and a 200 day moving average price of $54.19.

Amedisys Company Profile

Amedisys, Inc is a healthcare services company. The Company’s segments are Home Health, Hospice, Personal Care and Other. The Company is a provider of home health, hospice and personal care services. As of December 31, 2016, the Company owned and operated 327 Medicare-certified home healthcare centers, 79 Medicare-certified hospice care centers and 14 personal-care care centers in 34 states within the United States and the District of Columbia.

Get a free copy of the Zacks research report on Amedisys (AMED)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys Inc and related companies with MarketBeat.com's FREE daily email newsletter.